Listen to Professor Richard Haynes of Public engagement at Nuffield Department of Population Health inviting you to join our next online workshop on Tuesday 5 January at 7pm GMT to find out more about SGLT2 inhibitors/Flozins and kidney health. Previously used in the treatment of diabetes, SGLT2 Inhibitors/Flozins, approved for use in kidney patients, could be a treatment breakthrough for Alport syndrome patients as they’ve been proven to prolong kidney health. Find out more at the Zoom workshop – email research@alport.info for the Zoom link.
